Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Sarepta Therapeutics Stock Is Crashing Today


Shares of Sarepta Therapeutics (NASDAQ: SRPT) were crashing 43.6% lower as of 11:10 a.m. ET on Tuesday. The huge sell-off came after the company announced top-line results from its phase 3 Embark study evaluating Elevidys in treating young patients with Duchenne muscular dystrophy (DMD).

Sarepta said that the primary endpoint of the late-stage study wasn't met. Patients receiving Elevidys saw a 2.6-point improvement on the North Star Ambulatory Assessment (NSAA) total score 52 weeks after treatment. However, that wasn't statistically significant compared to the improvement experienced by patients receiving placebo. 

You might expect Sarepta's management team to express disappointment over Elevidys failing to meet the primary endpoint, but CEO Doug Ingram actually sounded upbeat. Ingram stated in a press release announcing the results that Sarepta plans "to move swiftly to request an update to expand the labeled indication to treat all patients." 

Continue reading


Source Fool.com

Sarepta Therapeutics Stock

€135.00
1.470%
There is an upward development for Sarepta Therapeutics compared to yesterday, with an increase of €1.95 (1.470%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Sarepta Therapeutics stock is not clear.
However, we have a potential of -3.7% for Sarepta Therapeutics as the target price of 130 € is below the current price of 135.0 €.
Like: 0
Share

Comments